Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.50 |
| ▸ | DRD3 | P35462 | 11/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410264 | 0.83 | DRD2 (0.45) | DRD2DRD3S1PR1KCNH2HDAC1 | |
| SCHEMBL12209953 | 0.77 | S1PR1 (0.62) | DRD2DRD3S1PR1KCNH2HDAC1 | |
| SCHEMBL12436076 | 0.73 | DRD2 (0.43) | DRD2DRD3KCNH2HDAC1 | |
| SCHEMBL8470488 | 0.70 | HDAC1 (0.57) | DRD2DRD3S1PR1KCNH2HDAC1 | |
| Hydrochloric Acid SCHEMBL7420584 | 0.69 | S1PR1 (0.54) | DRD2DRD3S1PR1KCNH2HDAC1 | |
| SCHEMBL7274054 | 0.68 | S1PR1 (0.62) | DRD2DRD3S1PR1HDAC1 | |
| SCHEMBL6219605 | 0.68 | HDAC1 (0.57) | DRD2DRD3KCNH2HDAC1 | |
| SCHEMBL7275516 | 0.68 | S1PR1 (0.55) | DRD2DRD3S1PR1KCNH2HDAC1 | |
| SCHEMBL7284086 | 0.67 | S1PR1 (0.48) | DRD2DRD3S1PR1KCNH2HDAC1 | |
| SCHEMBL13580803 | 0.67 | S1PR1 (0.39) | DRD2DRD3S1PR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009145286-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | DRD2 426/4885DRD3 488/4885S1PR1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.